陈晓飞 付良青 刘泽源 (军事医学科学院附属医院药理室 北京 100071)
关键词 多药耐药; P-糖蛋白;维拉帕米
中图分类号：R730.53
文献标识码：A
文章编号：1008-049X(2007)02-0239-03
肿瘤多药耐药(multidrug resistance, MDR)是指肿瘤细胞对一种抗肿瘤药物产生耐药性的同时，对结构和作用机制完全不同的多种抗肿瘤药物也产生交叉耐药性。肿瘤MDR是化疗失败的重要原因［1］。与MDR 有关的许多药物是临床上常用的化疗剂, 如: 多柔比星、柔红霉素、长春新碱、放线菌素D、丝裂霉素等一线药物。MDR的存在使临床医生在选择药物上非常棘手，大大限制了抗肿瘤药物疗效的发挥，因此解决肿瘤MDR是提高化疗疗效的关键……
作者简介：陈晓飞，女，在读硕士，研究方向：临床药理。
Tel：（010）66947268
E-mail:cxf728cxf@126.com
通讯作者：刘泽源，男，博士，硕士生导师。
研究方向：临床药理。
Tel：（010）66947251
E-mail:13311010528@165.com
参 考 文 献
1 Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal［J］. Cancer Cell International,2005,5:30
2 Arora A,Seth K,Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver ［J］. Carcinogenesis, 2004,25(6):941-949
3黄克峰，陈德荣，罗荣.化疗后乳腺癌P糖蛋白表达与预后关系［J］.药物流行病学杂志， 2002，11（5）：232-234
4 Lin JH,Yamazaki M .Clinical relevance of P-glycoprotein in drug therapy［J］.Drug Metab Rev,2003 ,35(4):417-54
5 BARRANCO.SAMC.Method and kit for testing tumors for drug sensitivity［P］.World(PTC) patent, WO9325705, 1993-12-23
6 Karen VC, Ross AD Mary WD. Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells［J］. Biochemical Pharmacology, 2001,62（4）:417-424
7 Tsuruo T, Tida H, Tsukago S, et al. Increased accumulation of vincristine and adriamycin in drugresistance P388 tumour cells following incubation with calcium antagonist and calmodulin inhibitors［J］. Cancer Res, 1982, 42(11): 4730-4733
8 Cowie FJ,Pinkerton CR,Phillips M,et al.Continuousin fusion verapamil with etoposide in relapsed or resistant paediatric cancers［J］. BrI Cancer, 1995, 71(4): 877-881
9 Berti E，Carrara M，Ragazzi E，et al. A comparison of the modulation of antiblastics cytotoxicity by verapamil and dipyridamole in a human colon carcinoma cell line［J］. Int J Oncol，1999,15(1):155-160
10 Wainer IW. Stereoisomers in clinical oncology:why it is important to know what the right and left hands are doing［J］.Ann Oncol,1993,4(2):7-13
11 Bissett D, Kerr DJ, Cassidy J, et al.Phase I and pharmacokinetic study of D-verapamil and doxorubicin［J］. Br J Cancer, 1991,64(6):1168-1171
12 Schuldes H.Reversal of multidrug resistance and increase in plasma membrance fluidity in CHO cells with R-verapamil and bile salts［J］.EUR J Cancer,2001,37(5):660-667
13 Schuldes H.Cytostatic sensitivity and MDR in bladder carcinoma cells:implica.tions for tumor therapy［J］.Int J Clin Pharmacol Ther,2000,38(4):204-208
14 Seemann O. Establishment and characterization of multidrug-resistant human bladder carcinoma cell line RT112/D21［J］.Urol Res, 1995,22(6):353-360
15 Bruserud O.In vitro effect of R-verapamil on acute myelogenous leukemia blast cells:studies of cytokine secretion and cytokine-dependent blast profliferation［J］.Cancer Chemother Pharmacol,1995,37(1-2):70-78
16 Visani G.Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors［J］. Ann Hematol,1993,66(6):273-276
17 Bruserud O .Effects of dipyridamole and R-verapamil on in vitro proliferation of blast cells from patients with acute myelogenous leukaemia［J］.Leuk Res,1993,17(6):507-513
18 Wilson WH, Bates S, Fojo A,et al.Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy［J］. Clin Oncol, 1995, 13(8): 1985-1994
19 FANG G，YANG YL，LI JS，et al. R-dl-Verapamil downmodulates multidrug resistance of KBv200 cells to vincristine and doxorubicin［J］.Zhongguoyaolixuebao, 1999，20(7):647-650
20 Thurlimann B, Kroger N, Greiner J, et al. Dexverapamil to overcome epirubicin resistance in advanced breast cancer［J］. Clin Oncol,1995,121（3）:3-6
21 Lum BL,Fisher GA , Brophy NA ,et al. Clinical trials of modulation of multidrug resistance［J］. Cancer,1993,72(11):3502-14
22 Marzolini C,Paus E,Buclin T,et al.Polymophisms in human MDR(P-glycoprotein):recent advances and clinical relevance［J］. Clin Phamacol, 2004,75(1):13-33 资料来自:中国药师-专业站 |